Researchers studying the malaria parasite Plasmodium have found that a molecule known as Aurora-related kinase 1, or ARK1, acts as a central regulator during the parasite’s unusual form of cell division. Experiments showed that disabling this protein disrupted the parasite’s ability to replicate and prevented it from completing its life cycle in both human hosts and mosquito carriers.
Malaria remains a major global health threat, causing hundreds of thousands of deaths each year and infecting millions more across Africa, Asia and parts of Latin America. Although existing medicines and mosquito-control strategies have helped reduce mortality over the past two decades, the rise of drug-resistant parasite strains has intensified the search for new therapeutic targets.
Scientists say ARK1 appears to function as a molecular “traffic controller” that coordinates the distribution of genetic material when the parasite multiplies inside host cells. Unlike typical human cell division, malaria parasites undergo a highly specialised replication process involving multiple rounds of DNA duplication and nuclear division before individual daughter cells are formed. This unconventional biology has long puzzled researchers and made it difficult to identify weaknesses suitable for pharmaceutical intervention.
Laboratory experiments using genetically modified parasites demonstrated that when ARK1 activity was switched off, the replication process collapsed. Parasites failed to separate their chromosomes correctly, producing defective cells that could not continue developing. The disruption was observed not only during the parasite’s growth inside human red blood cells but also during stages of its life cycle inside mosquitoes.
Blocking the parasite’s ability to reproduce in both environments is particularly significant, researchers say, because it could halt malaria transmission altogether. Parasites that cannot complete their development inside mosquitoes cannot spread to new hosts when the insect feeds.
The discovery sheds light on one of the most complex aspects of malaria biology. Plasmodium parasites divide in a manner that differs markedly from most organisms, with rapid nuclear multiplication occurring before the formation of separate cells. This process requires precise control mechanisms to ensure chromosomes are distributed accurately.
ARK1 appears to orchestrate this process by guiding the parasite’s spindle apparatus, a structure that separates duplicated chromosomes during cell division. Without the protein’s regulatory role, the system becomes disorganised, leading to fatal errors in genetic segregation.
Scientists involved in the work say the findings demonstrate that ARK1 is indispensable across multiple stages of the parasite’s life cycle. Such consistency makes it an attractive target for new antimalarial drugs, since treatments that disable this protein could attack the parasite at different points of infection.
Current antimalarial therapies typically target processes involved in the parasite’s metabolism or its ability to invade red blood cells. However, many of these drugs face declining effectiveness as resistant strains emerge. Health authorities have warned that resistance to widely used treatments, including artemisinin-based combinations, threatens to undermine decades of progress against the disease.
Researchers say targeting proteins involved in cell division offers an alternative strategy that could bypass existing resistance mechanisms. Because ARK1 plays a fundamental role in parasite replication, blocking its activity may prove difficult for the organism to evade through genetic mutation.
Drug development based on the discovery will require further investigation, including structural studies to determine how ARK1 functions at a molecular level and whether compounds can be designed to inhibit it selectively without harming human cells. Aurora kinases also exist in humans, where they regulate cell division, so any therapeutic approach must ensure that medicines act specifically on the parasite’s version of the protein.
Scientists note that the parasite’s ARK1 has structural differences from human counterparts, which may provide an opportunity for targeted drug design. Advances in molecular modelling and high-throughput screening are expected to accelerate the search for compounds capable of interfering with the protein’s activity.
Malaria control efforts have made measurable progress over the past two decades through a combination of insecticide-treated bed nets, improved diagnostics and effective drug treatments. Yet the disease continues to impose a heavy burden on many low-income regions, particularly sub-Saharan Africa where children account for a large proportion of fatalities.
Follow Arabian Post
Select Arabian Post as your preferred source on Google and MSN News for trusted business news and Arab politics and updates.
